Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B is a research paper published in Molecular Therapy (2020). On theSindex it has a DataRank of 0. It has been cited 210 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: P01 HL64190
National Institutes of Health
Grant: K08 HL 146991-01
NHLBI NIH HHS
Grant: K08 HL140078
NHLBI NIH HHS
Grant: K08 HL146991
NHLBI NIH HHS
Grant: P01 HL064190
FWCI
19.43
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 2 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 1 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 1 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 4 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 4 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 3 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 3 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin